Journal
BIOANALYSIS
Volume 14, Issue 9, Pages 589-601Publisher
Newlands Press Ltd
DOI: 10.4155/bio-2022-0015
Keywords
antisense oligonucleotide; ASO; bioanalysis; GLP; hybridization; LC-MS; MS; validation
Ask authors/readers for more resources
The GLP validation and application of ASO bioanalysis using the hybridization LC-MS/MS platform was reported for the first time. The method, combining the advantages of ligand binding and LC-MS/MS, successfully quantified an ASO drug candidate in monkey serum, CSF, and tissues.
Background: Antisense oligonucleotide (ASO), an emerging modality in drug research and development, demands accurate and sensitive bioanalysis to understand its pharmacokinetic and pharmacodynamic properties. Results: By combining the advantages of both ligand binding and liquid chromatography-mass spectrometry/tandem mass (LC-MS/MS), hybridization LC-MS/MS methods were successfully developed and validated/qualified in a good lab practice (GLP) environment for the quantitation of an ASO drug candidate in monkey serum, cerebrospinal fluid (CSF) and tissues in the range of 0.5-500 ng/ml. Special treatment of CSF samples was employed to mitigate nonspecific binding, improve long-term storage stability and enable the usage of artificial CSF as a more accessible surrogate matrix. The method was also qualified and applied to ASO quantitation in various monkey tissue samples using a cocktail tissue homogenate as a surrogate matrix. Conclusion: This work was the first reported GLP validation and application of ASO bioanalysis using the hybridization LC-MS/MS platform.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available